Activin A Circulating Levels in Patients with Bone Metastasis from Breast or Prostate Cancer

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2006 Jul 15

PMID 16841234

Citations 46

Authors

Gaetano Leto

Lorena Incorvaia

Giuseppe Badalamenti

Francesca M Tumminello

Nicola Gebbia

Carla Flandina

Marilena Crescimanno

Giovambattista Rini

Affiliations

Soon will be listed here.

Abstract

Recent studies have highlighted that Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily, may be involved in the regulation of osteoblastic activity and in osteoclast differentiation. Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis. Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy blood donors (HS) of both sex (25 female and 23 male). Activin A serum concentrations were significantly increased in BC or PC patients as compared to OP (P < 0.0001) or BPH (P = 0.045), respectively, or to sex matched HS (P < 0.0001). Additionally, these levels resulted more elevated in PC patients as compared to BC patients (P = 0.032). Interestingly, Activin A was significantly higher in BM+ patients than in BM- patients (BC, P = 0.047; PC, P = 0.016). In BC patients, a significant correlation was observed only between Activin A and number of bone metastases (P = 0.0065) while, in PC patients, Activin A levels were strongly correlated with the Gleason score (P = 0.011) or PSA levels (P = 0.0001) and, to a lessen extent, with the number of bone metastases (P = 0.056). Receiver operating characteristic curve (ROC) analysis showed a fair diagnostic accuracy of Activin A to discriminate between BM+ and BM- patients (BC: AUC = 0.71 +/- 0.09, P = 0.03; PC: AUC = 0.73 +/- 0.081, P = 0.005). These findings indicate that Activin A may be implicated in the pathogenesis of bone metastasis. Therefore, this cytokine may be considered a novel potential target for a more selective therapeutic approach in the treatment of skeletal metastasis and may be also useful as additional biochemical marker of metastatic bone disease.

Citing Articles

Macrophages promote anti-androgen resistance in prostate cancer bone disease.

Li X, Selli C, Zhou H, Cao J, Wu S, Ma R J Exp Med. 2023; 220(4).

PMID: 36749798 PMC: 9948761. DOI: 10.1084/jem.20221007.

Activin A Causes Muscle Atrophy through MEF2C-Dependent Impaired Myogenesis.

Loumaye A, Lause P, Zhong X, Zimmers T, Bindels L, Thissen J Cells. 2022; 11(7).

PMID: 35406681 PMC: 8997966. DOI: 10.3390/cells11071119.

Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers.

Mallard J, Hucteau E, Hureau T, Pagano A Front Cell Dev Biol. 2021; 9:719643.

PMID: 34595171 PMC: 8476809. DOI: 10.3389/fcell.2021.719643.

Dual Roles of the Activin Signaling Pathway in Pancreatic Cancer.

Qiu W, Kuo C, Tian Y, Su G Biomedicines. 2021; 9(7).

PMID: 34356885 PMC: 8301451. DOI: 10.3390/biomedicines9070821.

Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.

Siff T, Parajuli P, Razzaque M, Atfi A Trends Endocrinol Metab. 2021; 32(6):382-402.

PMID: 33888422 PMC: 8102392. DOI: 10.1016/j.tem.2021.03.007.

References

Schulte K, Jonas C, Krebs R, Roher H . Activin A and activin receptors in thyroid cancer. Thyroid. 2001; 11(1):3-14. DOI: 10.1089/10507250150500603. View

Kleeff J, Ishiwata T, Friess H, Buchler M, Korc M . Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer. 1998; 77(6):860-8. DOI: 10.1002/(sici)1097-0215(19980911)77:6<860::aid-ijc11>3.0.co;2-5. View

Fujii Y, Kawakami S, Okada Y, Kageyama Y, Kihara K . Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab. 2004; 286(6):E927-31. DOI: 10.1152/ajpendo.00443.2003. View

Sakai R, Eto Y . Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol. 2001; 180(1-2):183-8. DOI: 10.1016/s0303-7207(01)00496-8. View

. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997; 277(11):925-6. View

Sugatani T, Alvarez U, Hruska K . Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003; 90(1):59-67. DOI: 10.1002/jcb.10613. View

Lambert-Messerlian G, DePasquale S, Maybruck W, Steinhoff M, Gajewski W . Secretion of activin A in recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1999; 74(1):93-7. DOI: 10.1006/gyno.1999.5417. View

Tsuchida K . Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord. 2004; 4(2):157-66. DOI: 10.2174/1568008043339901. View

Harrison C, Gray P, Vale W, Robertson D . Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab. 2005; 16(2):73-8. DOI: 10.1016/j.tem.2005.01.003. View

10.

Dowling C, Risbridger G . The role of inhibins and activins in prostate cancer pathogenesis. Endocr Relat Cancer. 2001; 7(4):243-56. DOI: 10.1677/erc.0.0070243. View

11.

Roodman G . Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-64. DOI: 10.1056/NEJMra030831. View

12.

Chen Y, Lui H, Lin S, Lee J, Ying S . Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood). 2002; 227(2):75-87. DOI: 10.1177/153537020222700201. View

13.

Risbridger G, Schmitt J, Robertson D . Activins and inhibins in endocrine and other tumors. Endocr Rev. 2001; 22(6):836-58. DOI: 10.1210/edrv.22.6.0450. View

14.

Luisi S, Florio P, Reis F, Petraglia F . Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol. 2001; 145(3):225-36. DOI: 10.1530/eje.0.1450225. View

15.

Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H, Mori M . Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol. 2002; 22(1):75-80. View

16.

Schramm A, von Schuetz V, Christiansen H, Havers W, Papoutsi M, Wilting J . High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene. 2004; 24(4):680-7. DOI: 10.1038/sj.onc.1208087. View

17.

Reinholz M, Iturria S, Ingle J, Roche P . Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat. 2002; 74(3):255-69. DOI: 10.1023/a:1016339120506. View

18.

Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K . SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res. 2003; 63(22):7791-8. View

19.

Carey J, Sasur L, Kawakubo H, Gupta V, Christian B, Bailey P . Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth. Mol Endocrinol. 2003; 18(3):696-707. DOI: 10.1210/me.2003-0360. View

20.

Pirisi M, Fabris C, Luisi S, Santuz M, Toniutto P, Vitulli D . Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma. Cancer Detect Prev. 2000; 24(2):150-5. View